What development phase is Nexgard in?

Nexgard is FDA-approved (marketed).

What are the side effects of Nexgard?

Common side effects include Diarrhea, Vomiting, Lethargy, Itching, Dermatitis, Anorexia.

What is the generic name of Nexgard?

AFOXOLANER is the generic (nonproprietary) name of Nexgard.

Last reviewed 2026-04-20 · How we verify

Nexgard (AFOXOLANER)

FDA-approved active Small molecule Quality 0/100

Afoxolaner (Nexgard) is a marketed drug that effectively controls fleas and ticks by blocking their nicotinic acetylcholine receptors, disrupting nerve signal transmission. Its key strength lies in its mechanism of action, which provides broad-spectrum protection against parasites. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	AFOXOLANER
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

Diarrhea
Vomiting
Lethargy
Itching
Dermatitis
Anorexia
Muscle tremor
Nausea
Depression

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nexgard CI brief — competitive landscape report
Nexgard updates RSS · CI watch RSS